nodes	percent_of_prediction	percent_of_DWPC	metapath
Glipizide—CYP2C9—cardial valve—systemic scleroderma	0.0679	0.315	CbGeAlD
Glipizide—PPARG—dermis—systemic scleroderma	0.0481	0.223	CbGeAlD
Glipizide—CYP2C9—Leflunomide—systemic scleroderma	0.035	0.608	CbGbCtD
Glipizide—PPARG—artery—systemic scleroderma	0.0174	0.0807	CbGeAlD
Glipizide—PPARG—endothelium—systemic scleroderma	0.0147	0.0682	CbGeAlD
Glipizide—PPARG—blood vessel—systemic scleroderma	0.0135	0.0629	CbGeAlD
Glipizide—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0126	0.218	CbGbCtD
Glipizide—CYP3A4—Prednisone—systemic scleroderma	0.01	0.174	CbGbCtD
Glipizide—ABCC8—smooth muscle tissue—systemic scleroderma	0.00832	0.0386	CbGeAlD
Glipizide—PPARG—connective tissue—systemic scleroderma	0.00695	0.0322	CbGeAlD
Glipizide—KCNJ11—tendon—systemic scleroderma	0.00679	0.0315	CbGeAlD
Glipizide—PPARG—smooth muscle tissue—systemic scleroderma	0.00635	0.0295	CbGeAlD
Glipizide—PPARG—skin of body—systemic scleroderma	0.00627	0.0291	CbGeAlD
Glipizide—PPARG—digestive system—systemic scleroderma	0.00502	0.0233	CbGeAlD
Glipizide—PPARG—tendon—systemic scleroderma	0.00477	0.0222	CbGeAlD
Glipizide—PPARG—lung—systemic scleroderma	0.00419	0.0194	CbGeAlD
Glipizide—CYP2C9—digestive system—systemic scleroderma	0.00294	0.0136	CbGeAlD
Glipizide—CYP3A4—digestive system—systemic scleroderma	0.00224	0.0104	CbGeAlD
Glipizide—Vertigo—Lisinopril—systemic scleroderma	0.00111	0.00152	CcSEcCtD
Glipizide—Diarrhoea—Mometasone—systemic scleroderma	0.00111	0.00152	CcSEcCtD
Glipizide—Syncope—Lisinopril—systemic scleroderma	0.00111	0.00152	CcSEcCtD
Glipizide—Leukopenia—Lisinopril—systemic scleroderma	0.0011	0.00152	CcSEcCtD
Glipizide—Shock—Mycophenolic acid—systemic scleroderma	0.0011	0.00151	CcSEcCtD
Glipizide—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.00109	0.0015	CcSEcCtD
Glipizide—Loss of consciousness—Lisinopril—systemic scleroderma	0.00108	0.00149	CcSEcCtD
Glipizide—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00108	0.00149	CcSEcCtD
Glipizide—Visual disturbance—Methotrexate—systemic scleroderma	0.00107	0.00148	CcSEcCtD
Glipizide—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00107	0.00147	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00107	0.00147	CcSEcCtD
Glipizide—Anorexia—Mycophenolic acid—systemic scleroderma	0.00107	0.00147	CcSEcCtD
Glipizide—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00146	CcSEcCtD
Glipizide—Tension—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00146	CcSEcCtD
Glipizide—Insomnia—Leflunomide—systemic scleroderma	0.00106	0.00146	CcSEcCtD
Glipizide—Paraesthesia—Leflunomide—systemic scleroderma	0.00105	0.00145	CcSEcCtD
Glipizide—Myalgia—Lisinopril—systemic scleroderma	0.00105	0.00144	CcSEcCtD
Glipizide—Arthralgia—Lisinopril—systemic scleroderma	0.00105	0.00144	CcSEcCtD
Glipizide—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00144	CcSEcCtD
Glipizide—Anxiety—Lisinopril—systemic scleroderma	0.00105	0.00144	CcSEcCtD
Glipizide—Dyspnoea—Leflunomide—systemic scleroderma	0.00104	0.00144	CcSEcCtD
Glipizide—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00143	CcSEcCtD
Glipizide—Discomfort—Lisinopril—systemic scleroderma	0.00104	0.00143	CcSEcCtD
Glipizide—Dyspepsia—Leflunomide—systemic scleroderma	0.00103	0.00142	CcSEcCtD
Glipizide—Vomiting—Mometasone—systemic scleroderma	0.00103	0.00142	CcSEcCtD
Glipizide—Feeling abnormal—Azathioprine—systemic scleroderma	0.00102	0.00141	CcSEcCtD
Glipizide—Rash—Mometasone—systemic scleroderma	0.00102	0.0014	CcSEcCtD
Glipizide—Asthenia—Captopril—systemic scleroderma	0.00102	0.0014	CcSEcCtD
Glipizide—Dermatitis—Mometasone—systemic scleroderma	0.00102	0.0014	CcSEcCtD
Glipizide—Decreased appetite—Leflunomide—systemic scleroderma	0.00102	0.0014	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00102	0.0014	CcSEcCtD
Glipizide—Confusional state—Lisinopril—systemic scleroderma	0.00101	0.0014	CcSEcCtD
Glipizide—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00101	0.0014	CcSEcCtD
Glipizide—Headache—Mometasone—systemic scleroderma	0.00101	0.00139	CcSEcCtD
Glipizide—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00139	CcSEcCtD
Glipizide—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00101	0.00139	CcSEcCtD
Glipizide—Insomnia—Mycophenolic acid—systemic scleroderma	0.00101	0.00139	CcSEcCtD
Glipizide—Oedema—Lisinopril—systemic scleroderma	0.00101	0.00138	CcSEcCtD
Glipizide—Pruritus—Captopril—systemic scleroderma	0.00101	0.00138	CcSEcCtD
Glipizide—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.001	0.00138	CcSEcCtD
Glipizide—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.001	0.00138	CcSEcCtD
Glipizide—Constipation—Leflunomide—systemic scleroderma	0.001	0.00138	CcSEcCtD
Glipizide—Pain—Leflunomide—systemic scleroderma	0.001	0.00138	CcSEcCtD
Glipizide—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000996	0.00137	CcSEcCtD
Glipizide—Somnolence—Mycophenolic acid—systemic scleroderma	0.000993	0.00137	CcSEcCtD
Glipizide—Shock—Lisinopril—systemic scleroderma	0.00099	0.00136	CcSEcCtD
Glipizide—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000985	0.00136	CcSEcCtD
Glipizide—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000984	0.00135	CcSEcCtD
Glipizide—Abdominal pain—Azathioprine—systemic scleroderma	0.000981	0.00135	CcSEcCtD
Glipizide—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000974	0.00134	CcSEcCtD
Glipizide—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000973	0.00134	CcSEcCtD
Glipizide—Diarrhoea—Captopril—systemic scleroderma	0.000972	0.00134	CcSEcCtD
Glipizide—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000971	0.00134	CcSEcCtD
Glipizide—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000971	0.00134	CcSEcCtD
Glipizide—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000969	0.00133	CcSEcCtD
Glipizide—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000967	0.00133	CcSEcCtD
Glipizide—Feeling abnormal—Leflunomide—systemic scleroderma	0.000965	0.00133	CcSEcCtD
Glipizide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000965	0.00133	CcSEcCtD
Glipizide—Nausea—Mometasone—systemic scleroderma	0.000961	0.00132	CcSEcCtD
Glipizide—Anorexia—Lisinopril—systemic scleroderma	0.000959	0.00132	CcSEcCtD
Glipizide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000958	0.00132	CcSEcCtD
Glipizide—Pain—Mycophenolic acid—systemic scleroderma	0.000956	0.00131	CcSEcCtD
Glipizide—Constipation—Mycophenolic acid—systemic scleroderma	0.000956	0.00131	CcSEcCtD
Glipizide—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00095	0.00131	CcSEcCtD
Glipizide—Dizziness—Captopril—systemic scleroderma	0.00094	0.00129	CcSEcCtD
Glipizide—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000933	0.00128	CcSEcCtD
Glipizide—Urticaria—Leflunomide—systemic scleroderma	0.000931	0.00128	CcSEcCtD
Glipizide—Abdominal pain—Leflunomide—systemic scleroderma	0.000926	0.00127	CcSEcCtD
Glipizide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000921	0.00127	CcSEcCtD
Glipizide—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.00092	0.00127	CcSEcCtD
Glipizide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.00092	0.00127	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000917	0.00126	CcSEcCtD
Glipizide—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000917	0.00126	CcSEcCtD
Glipizide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000914	0.00126	CcSEcCtD
Glipizide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000914	0.00126	CcSEcCtD
Glipizide—Insomnia—Lisinopril—systemic scleroderma	0.00091	0.00125	CcSEcCtD
Glipizide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000909	0.00125	CcSEcCtD
Glipizide—Paraesthesia—Lisinopril—systemic scleroderma	0.000904	0.00124	CcSEcCtD
Glipizide—Vomiting—Captopril—systemic scleroderma	0.000904	0.00124	CcSEcCtD
Glipizide—Dyspnoea—Lisinopril—systemic scleroderma	0.000897	0.00123	CcSEcCtD
Glipizide—Rash—Captopril—systemic scleroderma	0.000896	0.00123	CcSEcCtD
Glipizide—Dermatitis—Captopril—systemic scleroderma	0.000895	0.00123	CcSEcCtD
Glipizide—Somnolence—Lisinopril—systemic scleroderma	0.000895	0.00123	CcSEcCtD
Glipizide—Headache—Captopril—systemic scleroderma	0.00089	0.00122	CcSEcCtD
Glipizide—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000889	0.00122	CcSEcCtD
Glipizide—Dyspepsia—Lisinopril—systemic scleroderma	0.000886	0.00122	CcSEcCtD
Glipizide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000883	0.00122	CcSEcCtD
Glipizide—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000882	0.00121	CcSEcCtD
Glipizide—Decreased appetite—Lisinopril—systemic scleroderma	0.000875	0.0012	CcSEcCtD
Glipizide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000869	0.0012	CcSEcCtD
Glipizide—Shock—Mycophenolate mofetil—systemic scleroderma	0.000868	0.00119	CcSEcCtD
Glipizide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000863	0.00119	CcSEcCtD
Glipizide—Hypersensitivity—Leflunomide—systemic scleroderma	0.000863	0.00119	CcSEcCtD
Glipizide—Constipation—Lisinopril—systemic scleroderma	0.000861	0.00118	CcSEcCtD
Glipizide—Pain—Lisinopril—systemic scleroderma	0.000861	0.00118	CcSEcCtD
Glipizide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000853	0.00117	CcSEcCtD
Glipizide—Diarrhoea—Azathioprine—systemic scleroderma	0.000849	0.00117	CcSEcCtD
Glipizide—Nausea—Captopril—systemic scleroderma	0.000844	0.00116	CcSEcCtD
Glipizide—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000842	0.00116	CcSEcCtD
Glipizide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000841	0.00116	CcSEcCtD
Glipizide—Asthenia—Leflunomide—systemic scleroderma	0.00084	0.00116	CcSEcCtD
Glipizide—Pancytopenia—Methotrexate—systemic scleroderma	0.000834	0.00115	CcSEcCtD
Glipizide—Feeling abnormal—Lisinopril—systemic scleroderma	0.000829	0.00114	CcSEcCtD
Glipizide—Pruritus—Leflunomide—systemic scleroderma	0.000829	0.00114	CcSEcCtD
Glipizide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000823	0.00113	CcSEcCtD
Glipizide—Dysuria—Methotrexate—systemic scleroderma	0.000821	0.00113	CcSEcCtD
Glipizide—Dizziness—Azathioprine—systemic scleroderma	0.00082	0.00113	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000803	0.00111	CcSEcCtD
Glipizide—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000802	0.0011	CcSEcCtD
Glipizide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000802	0.0011	CcSEcCtD
Glipizide—Diarrhoea—Leflunomide—systemic scleroderma	0.000801	0.0011	CcSEcCtD
Glipizide—Urticaria—Lisinopril—systemic scleroderma	0.0008	0.0011	CcSEcCtD
Glipizide—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000798	0.0011	CcSEcCtD
Glipizide—Abdominal pain—Lisinopril—systemic scleroderma	0.000796	0.00109	CcSEcCtD
Glipizide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000792	0.00109	CcSEcCtD
Glipizide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000791	0.00109	CcSEcCtD
Glipizide—Vomiting—Azathioprine—systemic scleroderma	0.000789	0.00108	CcSEcCtD
Glipizide—Eye disorder—Prednisone—systemic scleroderma	0.000786	0.00108	CcSEcCtD
Glipizide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000786	0.00108	CcSEcCtD
Glipizide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000784	0.00108	CcSEcCtD
Glipizide—Drowsiness—Methotrexate—systemic scleroderma	0.000783	0.00108	CcSEcCtD
Glipizide—Rash—Azathioprine—systemic scleroderma	0.000782	0.00108	CcSEcCtD
Glipizide—Dermatitis—Azathioprine—systemic scleroderma	0.000781	0.00107	CcSEcCtD
Glipizide—Flushing—Prednisone—systemic scleroderma	0.000781	0.00107	CcSEcCtD
Glipizide—Headache—Azathioprine—systemic scleroderma	0.000777	0.00107	CcSEcCtD
Glipizide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000776	0.00107	CcSEcCtD
Glipizide—Dizziness—Leflunomide—systemic scleroderma	0.000775	0.00107	CcSEcCtD
Glipizide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000767	0.00105	CcSEcCtD
Glipizide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000765	0.00105	CcSEcCtD
Glipizide—Conjunctivitis—Methotrexate—systemic scleroderma	0.000761	0.00105	CcSEcCtD
Glipizide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000761	0.00105	CcSEcCtD
Glipizide—Pain—Mycophenolate mofetil—systemic scleroderma	0.000754	0.00104	CcSEcCtD
Glipizide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000754	0.00104	CcSEcCtD
Glipizide—Arrhythmia—Prednisone—systemic scleroderma	0.000752	0.00103	CcSEcCtD
Glipizide—Sweating—Methotrexate—systemic scleroderma	0.000751	0.00103	CcSEcCtD
Glipizide—Vomiting—Leflunomide—systemic scleroderma	0.000745	0.00102	CcSEcCtD
Glipizide—Hypersensitivity—Lisinopril—systemic scleroderma	0.000742	0.00102	CcSEcCtD
Glipizide—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000741	0.00102	CcSEcCtD
Glipizide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000739	0.00102	CcSEcCtD
Glipizide—Rash—Leflunomide—systemic scleroderma	0.000739	0.00102	CcSEcCtD
Glipizide—Dermatitis—Leflunomide—systemic scleroderma	0.000738	0.00101	CcSEcCtD
Glipizide—Nausea—Azathioprine—systemic scleroderma	0.000737	0.00101	CcSEcCtD
Glipizide—Headache—Leflunomide—systemic scleroderma	0.000734	0.00101	CcSEcCtD
Glipizide—Erythema—Prednisone—systemic scleroderma	0.000732	0.00101	CcSEcCtD
Glipizide—Agranulocytosis—Methotrexate—systemic scleroderma	0.000731	0.00101	CcSEcCtD
Glipizide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000727	0.001	CcSEcCtD
Glipizide—Asthenia—Lisinopril—systemic scleroderma	0.000722	0.000993	CcSEcCtD
Glipizide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000721	0.000992	CcSEcCtD
Glipizide—Pruritus—Lisinopril—systemic scleroderma	0.000712	0.00098	CcSEcCtD
Glipizide—Vomiting—Mycophenolic acid—systemic scleroderma	0.00071	0.000977	CcSEcCtD
Glipizide—Rash—Mycophenolic acid—systemic scleroderma	0.000705	0.000969	CcSEcCtD
Glipizide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000704	0.000968	CcSEcCtD
Glipizide—Hepatitis—Methotrexate—systemic scleroderma	0.000703	0.000967	CcSEcCtD
Glipizide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000701	0.000964	CcSEcCtD
Glipizide—Headache—Mycophenolic acid—systemic scleroderma	0.0007	0.000963	CcSEcCtD
Glipizide—Pharyngitis—Methotrexate—systemic scleroderma	0.000698	0.00096	CcSEcCtD
Glipizide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000697	0.000959	CcSEcCtD
Glipizide—Nausea—Leflunomide—systemic scleroderma	0.000696	0.000957	CcSEcCtD
Glipizide—Vision blurred—Prednisone—systemic scleroderma	0.00069	0.000949	CcSEcCtD
Glipizide—Diarrhoea—Lisinopril—systemic scleroderma	0.000689	0.000947	CcSEcCtD
Glipizide—Ill-defined disorder—Prednisone—systemic scleroderma	0.00068	0.000935	CcSEcCtD
Glipizide—Visual impairment—Methotrexate—systemic scleroderma	0.000678	0.000932	CcSEcCtD
Glipizide—Dizziness—Lisinopril—systemic scleroderma	0.000666	0.000916	CcSEcCtD
Glipizide—Nausea—Mycophenolic acid—systemic scleroderma	0.000664	0.000913	CcSEcCtD
Glipizide—Malaise—Prednisone—systemic scleroderma	0.000661	0.000909	CcSEcCtD
Glipizide—Vertigo—Prednisone—systemic scleroderma	0.000658	0.000905	CcSEcCtD
Glipizide—Eye disorder—Methotrexate—systemic scleroderma	0.000657	0.000904	CcSEcCtD
Glipizide—Syncope—Prednisone—systemic scleroderma	0.000657	0.000903	CcSEcCtD
Glipizide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00065	0.000894	CcSEcCtD
Glipizide—Loss of consciousness—Prednisone—systemic scleroderma	0.000644	0.000886	CcSEcCtD
Glipizide—Vomiting—Lisinopril—systemic scleroderma	0.00064	0.00088	CcSEcCtD
Glipizide—Rash—Lisinopril—systemic scleroderma	0.000635	0.000873	CcSEcCtD
Glipizide—Dermatitis—Lisinopril—systemic scleroderma	0.000634	0.000872	CcSEcCtD
Glipizide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000633	0.00087	CcSEcCtD
Glipizide—Hypertension—Prednisone—systemic scleroderma	0.000632	0.00087	CcSEcCtD
Glipizide—Chills—Methotrexate—systemic scleroderma	0.000631	0.000868	CcSEcCtD
Glipizide—Headache—Lisinopril—systemic scleroderma	0.000631	0.000867	CcSEcCtD
Glipizide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000624	0.000858	CcSEcCtD
Glipizide—Myalgia—Prednisone—systemic scleroderma	0.000624	0.000858	CcSEcCtD
Glipizide—Arthralgia—Prednisone—systemic scleroderma	0.000624	0.000858	CcSEcCtD
Glipizide—Anxiety—Prednisone—systemic scleroderma	0.000621	0.000855	CcSEcCtD
Glipizide—Discomfort—Prednisone—systemic scleroderma	0.000616	0.000847	CcSEcCtD
Glipizide—Erythema—Methotrexate—systemic scleroderma	0.000612	0.000842	CcSEcCtD
Glipizide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000603	0.00083	CcSEcCtD
Glipizide—Nausea—Lisinopril—systemic scleroderma	0.000598	0.000822	CcSEcCtD
Glipizide—Oedema—Prednisone—systemic scleroderma	0.000598	0.000822	CcSEcCtD
Glipizide—Shock—Prednisone—systemic scleroderma	0.000588	0.000809	CcSEcCtD
Glipizide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000583	0.000802	CcSEcCtD
Glipizide—Hyperhidrosis—Prednisone—systemic scleroderma	0.000578	0.000795	CcSEcCtD
Glipizide—Vision blurred—Methotrexate—systemic scleroderma	0.000577	0.000794	CcSEcCtD
Glipizide—Anorexia—Prednisone—systemic scleroderma	0.00057	0.000784	CcSEcCtD
Glipizide—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000568	0.000781	CcSEcCtD
Glipizide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000561	0.000771	CcSEcCtD
Glipizide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000556	0.000765	CcSEcCtD
Glipizide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000556	0.000764	CcSEcCtD
Glipizide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000552	0.00076	CcSEcCtD
Glipizide—Malaise—Methotrexate—systemic scleroderma	0.000552	0.000759	CcSEcCtD
Glipizide—Vertigo—Methotrexate—systemic scleroderma	0.00055	0.000756	CcSEcCtD
Glipizide—Leukopenia—Methotrexate—systemic scleroderma	0.000548	0.000754	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000545	0.000749	CcSEcCtD
Glipizide—Insomnia—Prednisone—systemic scleroderma	0.000541	0.000744	CcSEcCtD
Glipizide—Paraesthesia—Prednisone—systemic scleroderma	0.000537	0.000738	CcSEcCtD
Glipizide—Dyspepsia—Prednisone—systemic scleroderma	0.000526	0.000724	CcSEcCtD
Glipizide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000524	0.000721	CcSEcCtD
Glipizide—Myalgia—Methotrexate—systemic scleroderma	0.000521	0.000717	CcSEcCtD
Glipizide—Arthralgia—Methotrexate—systemic scleroderma	0.000521	0.000717	CcSEcCtD
Glipizide—Decreased appetite—Prednisone—systemic scleroderma	0.00052	0.000715	CcSEcCtD
Glipizide—Discomfort—Methotrexate—systemic scleroderma	0.000515	0.000708	CcSEcCtD
Glipizide—Constipation—Prednisone—systemic scleroderma	0.000511	0.000703	CcSEcCtD
Glipizide—Confusional state—Methotrexate—systemic scleroderma	0.000504	0.000693	CcSEcCtD
Glipizide—Feeling abnormal—Prednisone—systemic scleroderma	0.000493	0.000678	CcSEcCtD
Glipizide—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000489	0.000673	CcSEcCtD
Glipizide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000489	0.000672	CcSEcCtD
Glipizide—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000483	0.000664	CcSEcCtD
Glipizide—Anorexia—Methotrexate—systemic scleroderma	0.000476	0.000655	CcSEcCtD
Glipizide—Urticaria—Prednisone—systemic scleroderma	0.000475	0.000653	CcSEcCtD
Glipizide—Abdominal pain—Prednisone—systemic scleroderma	0.000473	0.00065	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000455	0.000626	CcSEcCtD
Glipizide—Insomnia—Methotrexate—systemic scleroderma	0.000452	0.000622	CcSEcCtD
Glipizide—Paraesthesia—Methotrexate—systemic scleroderma	0.000449	0.000617	CcSEcCtD
Glipizide—Dyspnoea—Methotrexate—systemic scleroderma	0.000445	0.000613	CcSEcCtD
Glipizide—Somnolence—Methotrexate—systemic scleroderma	0.000444	0.000611	CcSEcCtD
Glipizide—Hypersensitivity—Prednisone—systemic scleroderma	0.00044	0.000606	CcSEcCtD
Glipizide—Dyspepsia—Methotrexate—systemic scleroderma	0.00044	0.000605	CcSEcCtD
Glipizide—Decreased appetite—Methotrexate—systemic scleroderma	0.000434	0.000597	CcSEcCtD
Glipizide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000431	0.000593	CcSEcCtD
Glipizide—Asthenia—Prednisone—systemic scleroderma	0.000429	0.00059	CcSEcCtD
Glipizide—Pain—Methotrexate—systemic scleroderma	0.000427	0.000588	CcSEcCtD
Glipizide—Pruritus—Prednisone—systemic scleroderma	0.000423	0.000582	CcSEcCtD
Glipizide—Feeling abnormal—Methotrexate—systemic scleroderma	0.000412	0.000566	CcSEcCtD
Glipizide—Diarrhoea—Prednisone—systemic scleroderma	0.000409	0.000563	CcSEcCtD
Glipizide—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000409	0.000562	CcSEcCtD
Glipizide—Urticaria—Methotrexate—systemic scleroderma	0.000397	0.000546	CcSEcCtD
Glipizide—Dizziness—Prednisone—systemic scleroderma	0.000395	0.000544	CcSEcCtD
Glipizide—Abdominal pain—Methotrexate—systemic scleroderma	0.000395	0.000543	CcSEcCtD
Glipizide—Vomiting—Prednisone—systemic scleroderma	0.00038	0.000523	CcSEcCtD
Glipizide—Rash—Prednisone—systemic scleroderma	0.000377	0.000518	CcSEcCtD
Glipizide—Dermatitis—Prednisone—systemic scleroderma	0.000377	0.000518	CcSEcCtD
Glipizide—Headache—Prednisone—systemic scleroderma	0.000374	0.000515	CcSEcCtD
Glipizide—Hypersensitivity—Methotrexate—systemic scleroderma	0.000368	0.000506	CcSEcCtD
Glipizide—Asthenia—Methotrexate—systemic scleroderma	0.000358	0.000493	CcSEcCtD
Glipizide—Nausea—Prednisone—systemic scleroderma	0.000355	0.000488	CcSEcCtD
Glipizide—Pruritus—Methotrexate—systemic scleroderma	0.000353	0.000486	CcSEcCtD
Glipizide—Diarrhoea—Methotrexate—systemic scleroderma	0.000342	0.00047	CcSEcCtD
Glipizide—Dizziness—Methotrexate—systemic scleroderma	0.00033	0.000454	CcSEcCtD
Glipizide—Vomiting—Methotrexate—systemic scleroderma	0.000318	0.000437	CcSEcCtD
Glipizide—Rash—Methotrexate—systemic scleroderma	0.000315	0.000433	CcSEcCtD
Glipizide—Dermatitis—Methotrexate—systemic scleroderma	0.000315	0.000433	CcSEcCtD
Glipizide—Headache—Methotrexate—systemic scleroderma	0.000313	0.00043	CcSEcCtD
Glipizide—Nausea—Methotrexate—systemic scleroderma	0.000297	0.000408	CcSEcCtD
